- Home
- ALLO vs ILLR Comparison
ALLO vs ILLR Comparison
Compare ALLO & ILLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ILLR
- Stock Information
- Founded
- ALLO 2017
- ILLR 2015
- Country
- ALLO United States
- ILLR United States
- Employees
- ALLO N/A
- ILLR N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ILLR Investment Managers
- Sector
- ALLO Health Care
- ILLR Finance
- Exchange
- ALLO Nasdaq
- ILLR Nasdaq
- Market Cap
- ALLO 277.8M
- ILLR N/A
- IPO Year
- ALLO 2018
- ILLR N/A
- Fundamental
- Price
- ALLO $1.21
- ILLR $0.74
- Analyst Decision
- ALLO Strong Buy
- ILLR
- Analyst Count
- ALLO 9
- ILLR 0
- Target Price
- ALLO $8.44
- ILLR N/A
- AVG Volume (30 Days)
- ALLO 2.5M
- ILLR 1.3M
- Earning Date
- ALLO 08-06-2025
- ILLR 08-15-2025
- Dividend Yield
- ALLO N/A
- ILLR N/A
- EPS Growth
- ALLO N/A
- ILLR N/A
- EPS
- ALLO N/A
- ILLR N/A
- Revenue
- ALLO N/A
- ILLR $45,244,000.00
- Revenue This Year
- ALLO N/A
- ILLR N/A
- Revenue Next Year
- ALLO $199.63
- ILLR N/A
- P/E Ratio
- ALLO N/A
- ILLR N/A
- Revenue Growth
- ALLO N/A
- ILLR N/A
- 52 Week Low
- ALLO $0.86
- ILLR $0.51
- 52 Week High
- ALLO $3.78
- ILLR $6.52
- Technical
- Relative Strength Index (RSI)
- ALLO 43.33
- ILLR N/A
- Support Level
- ALLO $1.11
- ILLR N/A
- Resistance Level
- ALLO $1.29
- ILLR N/A
- Average True Range (ATR)
- ALLO 0.09
- ILLR 0.00
- MACD
- ALLO -0.01
- ILLR 0.00
- Stochastic Oscillator
- ALLO 24.19
- ILLR 0.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.